top of page

Roche completes acquisition of Spark Therapeutics

  • Writer: ipharmaservices
    ipharmaservices
  • Dec 18, 2019
  • 1 min read

The company announced that Spark would continue operations in Philadelphia


Basel: Roche and Spark announced that the acquisition completed following the approval from the government agencies.


The company announced that Spark Therapeutics would continue its operations in Philadelphia within the Roche group. Roche completed the subsidiary through a merger of 022019 Merger Subsidiary, Inc. The shares were purchased for USD 114.50 per share in cash.




Severin Schwan, CEO of Roche, said, “We are excited about this important milestone because we believe that together, Roche and Spark will be able to improve the lives of patients through innovative gene therapies significantly.”


Spark Therapeutics is a commercial company involved in developing gene therapies for genetic disorders. Spark Therapeutics involved in developing cures for blindness, hemophilia, lysosomal storage disorders, and neurodegenerative diseases — the company founded in March 2013.

Recent Posts

See All

Comments


For sponsored articles, link insertions, and advertisements, please write to info@ipharmacenter.com

Find the latest pharma and healthcare news on Telegram now. Simply scan the QR code. 

Rephrase with Ginger (Cmd+⌥+E)
iPharmaCenter Telegran_edited.jpg
bottom of page